Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy

Oncologist

Volumn 13, Issue 12, 2008, Pages 1235-1245

  Penault Llorca, Frédérique ^a,b,c   Abrial, Catherine ^a   Raoelfils, Inès ^a   Chollet, Philippe ^a,b,c   Cayre, Anne ^a   Mouret Reynier, Marie Ange ^a,b   Thivat, Emilie ^a   Mishellany, Florence ^a,b   Gimbergues, Pierre ^a,b   Durando, Xavier ^a,b  

^a CENTRE JEAN PERRIN   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c Centre d'investigation clinique   (France)

Author keywords

Breast cancer; Cyclin D1; Cyclo oxygenase 2; Ki 67; Mitotic index

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; NAVELBINE; PACLITAXEL; PIRARUBICIN; TAMOXIFEN; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MENOPAUSE; MITOSIS INDEX; MULTIPLE CYCLE TREATMENT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLIN D1; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; MITOTIC INDEX; PROGNOSIS;

EID: 58749085047     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0073     Document Type: Article

References (38)

1. Buchholz TA, Hunt KK, Whitman GJ et al. Neoadjuvant chemotherapy for breast carcinoma: Multidisciplinary considerations of benefits and risks. Cancer 2003;98:1150-1160.
2. Abrial C, Penault-Llorca F, Delva R et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: A retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 2005;94: 255-263.
3. Penault-Llorca F, Abrial C, Mouret-Reynier MA et al. Achieving higher pathological complete response rates in HER-2-positive patients with induction chemotherapy without trastuzumab in operable breast cancer. The Oncologist 2007;12:390-396.
4. Tacca O, Penault-Llorca F, Abrial C et al. Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy. The Oncologist 2007;12:636-643.
5. Chevallier B, Roche H, Olivier JP et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993;16:223-228.
6. Sataloff DM, Mason BA, Prestipino AJ et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome. J Am Coll Surg 1995;180:297-306.
7. Chollet P, Charrier S, Brain E et al. Clinical and pathological response to primary chemotherapy in inoperable breast cancer. Eur J Cancer 1997;36: 862-866.
8. Van Praagh I, Curé H, Leduc B et al. Efficacy of a primary regimen combining vinorelbine, epirubicin and methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer. The Oncologist 2002; 7:418-423.
9. Amat S, Bougnoux P, Penault-Llorca F et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 2003;88:1339-1345.
10. Abrial C, Mouret-Reynier MA, Amat S et al. Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancers. Med Oncol 2005;22:233-240.
11. Amat S, Mouret-Reynier MA, Penault-Llorca F et al. Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer. Clin Breast Cancer 2006;7:262-269.
12. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up Histopathology 1991;19:403-410.
13. Kaplan EL, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1957;53:457-471.
14. Waller U. [Giant nuclei after myleran therapy and splenic irradiation in chronic myeloid leukemia.] Pathol Microbiol (Basel) 1960;23:283-290. In German.
15. Penault-Llorca F, Cayre A, Bouchet Mishellany F et al. Induction chemotherapy for breast carcinoma: Predictive markers and relation with outcome. Int J Oncol 2003;22:1319-1325.
16. Amat S, Penault-Llorca F, Cure H et al. Scarff-Bloom-Richardson (SBR) grading: A pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 2002;20: 791-796.
17. Vincent-Salomon A, Rousseau A, Jouve M et al.; Breast Cancer Study Group. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer 2004;40:1502-1508.
18. Collecchi P, Baldini E, Giannessi P et al. Primary chemotherapy in locally advanced breast cancer (LABC): Effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers. Eur J Cancer 1998;34:1701-1704.
19. Chang J, Ormerod M, Powles TJ et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000;89:2145-2152.
20. Burcombe RJ, Makris A, Richman PI et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 2005;92:147-155.
21. Méklati el-HM, Lévy P, O'Toole D et al. Granular cell tumor of the pancreas. Pancreas 2005;31:296-298.
22. Costa C, Soares R, Reis-Filho JS et al. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002;55:429-434.
23. Simpson JF, Gray R, Dressler LG et al. Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: Results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 2000;18:2059-2069.
24. Laroye GJ, Minkin S. The impact of mitotic index on predicting outcome in breast carcinoma: A comparison of different counting methods in patients with different lymph node status. Mod Pathol 1991;4:456-460.
25. Rozan S, Vincent-Salomon A, Zafrani B et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 1998;79:27-33.
26. Michalides R, Hageman P, Van Tinteren H et al. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 1996;73:728-734.
27. Barbareschi M, Pelosio P, Caffo O et al. Cyclin-D1-gene amplification and expression in breast carcinoma: Relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. Int J Cancer 1997;74:171-174.
28. Umekita Y, Ohi Y, Sagara Y et al. Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer 2002;98:415-418.
29. Gillett C, Smith P, Gregory W et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer 1996;69:92-99.
30. Denkert C, Winzer KJ, Ml̈ler BM et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003;97:2978-2987.
31. Ristimäki A, Sivula A, Lundin J et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-635.
32. Sivula A, Talvensaari-Mattila A, Lundin J et al. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 2005;89:215-220.
33. Brain E, Garrino C, Misset JL et al. Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. Br J Cancer 1997;75:1360-1367.
34. Bonadonna G, Valagussa P, Brambilla C et al. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998;16:93-100.
35. Eltahir A, Heys SD, Hutcheon AW et al. Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy. Am J Surg 1998;175:127-132.
36. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
37. Kuerer HM, Newman LA, Buzdar AU et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 1998;176: 502-509.
38. Chollet P, Amat S, Cure H et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002;86:1041-1046.